ClinicalTrials.gg
CompletedNCT02117648Updated Jan 7, 2019Results posted

A Study of LY2835219 in Participants With Cancer

A Phase 1 interventional study of Abemaciclib and Clarithromycin in Neoplasm and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-07.

Primary conditionNeoplasm MetastasisRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm Metastasis
Why
  1. The study's listed conditions name Neoplasm Metastasis, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing abemaciclib in Neoplasm Metastasis — 3 open to participants now, 8 under way, 3 of them phase 3. abemaciclib · Neoplasm Metastasis.

Enrollment
11th of 15
26 · median 48
Started
2014
the only one that year
Phase 1
5 of 15
none open now
Registered
2nd of 15
by date
Lead sponsor
9 of 15
Eli Lilly and Company

Among the 15 studies testing abemaciclib in Neoplasm Metastasis, this one is the 11th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 1, and was the 2nd registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

3 of the 15 studies testing abemaciclib in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing abemaciclib in Neoplasm Metastasis, or all of them as a file.
02

Study summary

The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied.

Each participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met.

03

Conditions studied

  • Neoplasm
  • Neoplasm Metastasis

Browse trials for

Keywords

  • advanced cancer
  • metastatic cancer
04

In context

Neoplasm Metastasis Reclassified

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

This study's enrollment of 26 is below the median of 50 across 3,270 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological or cytological evidence of cancer (solid tumors) that is advanced and/or
  • Have a performance status of 0 to 2 on the (ECOG) scale

Exclusion criteria

Exclusion Criteria:

  • No symptomatic central nervous system (CNS) or
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Abemaciclib Alone Period 1

    50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib + Clarithromycin Period 2

    Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.

    Drug: Abemaciclib · Drug: Clarithromycin

  • Experimental
    Abemaciclib Safety Extension

    After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.

    Drug: Abemaciclib

Interventions

07

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib

    Time frame: Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose

  2. PK: Maximum Concentration (Cmax) of Abemaciclib

    Time frame: Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96,120,144,168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose

08

Results

Posted Aug 2, 2018

Participant flow

Abemaciclib Alone Period 1
Participant flow — Abemaciclib Alone Period 1
MilestoneAbemaciclib Alone Then Abemaciclib + Clarithromycin
Started26
Received at least 1 dose of study drug26
Completed24
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Adverse event1
Abemaciclib + Clarithromycin Period 2
Participant flow — Abemaciclib + Clarithromycin Period 2
MilestoneAbemaciclib Alone Then Abemaciclib + Clarithromycin
Started24
Received at least 1 dose of study drug21
Completed20
Not completed4
Withdrew: Progressive disease1
Withdrew: Death1
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Abemaciclib Safety-Extension Phase
Participant flow — Abemaciclib Safety-Extension Phase
MilestoneAbemaciclib Alone Then Abemaciclib + Clarithromycin
Started20
Completed0
Not completed20
Withdrew: Progressive disease12
Withdrew: Physician decision1
Withdrew: Death3
Withdrew: Withdrawal by subject2
Withdrew: Adverse event2

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib
Time frame:
Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose
Reported as:
Geometric mean · nanogram*hour/milliliter(mL) ng*h/mL
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib
nanogram*hour/milliliter(mL) ng*h/mLAbemaciclib Period 1Abemaciclib + Clarithromycin Period 2
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib2230 ± 936850 ± 66
PrimaryPK: Maximum Concentration (Cmax) of Abemaciclib
Time frame:
Period 1: Predose; 1, 2, 4, 6, 8, 10, 24, 48, 72, 96,120,144,168hr, Period 2: 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240hr Post dose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Abemaciclib
nanogram/milliliter (ng/mL)Abemaciclib Period 1Abemaciclib + Clarithromycin Period 2
PK: Maximum Concentration (Cmax) of Abemaciclib70.0 ± 7384.3 ± 55

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib—1/26 (3.8%)13/26 (50%)
Clarithromycin—1/24 (4.2%)7/24 (29.2%)
Abemaciclib + Clarithromycin—1/21 (4.8%)10/21 (47.6%)
Safety Extension Abemaciclib—15/20 (75%)19/20 (95%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventAbemaciclibClarithromycinAbemaciclib + ClarithromycinSafety Extension Abemaciclib
Small intestinal obstructionGastrointestinal disorders0/260/240/213/20
Atrial fibrillationCardiac disorders0/260/240/212/20
AnaemiaBlood and lymphatic system disorders0/260/241/211/20
Sinus tachycardiaCardiac disorders0/260/240/211/20
Abdominal painGastrointestinal disorders0/260/240/211/20
AscitesGastrointestinal disorders0/260/240/211/20
DiarrhoeaGastrointestinal disorders0/260/240/211/20
Gastrointestinal haemorrhageGastrointestinal disorders0/260/240/211/20
NauseaGastrointestinal disorders0/260/240/211/20
VomitingGastrointestinal disorders0/260/240/211/20
Most frequent other events
Showing 10 of 39
Most frequent other events
EventAbemaciclibClarithromycinAbemaciclib + ClarithromycinSafety Extension Abemaciclib
FatigueGeneral disorders1/261/241/2114/20
AnaemiaBlood and lymphatic system disorders3/260/242/2112/20
DiarrhoeaGastrointestinal disorders0/260/241/2112/20
NauseaGastrointestinal disorders3/261/241/219/20
Neutrophil count decreasedInvestigations0/261/240/219/20
Blood creatinine increasedInvestigations2/260/241/218/20
HypokalaemiaMetabolism and nutrition disorders0/260/241/218/20
VomitingGastrointestinal disorders1/262/241/217/20
HypomagnesaemiaMetabolism and nutrition disorders1/260/240/215/20
Abdominal painGastrointestinal disorders2/260/241/214/20

Baseline characteristics

Age, Customized
Age, Customized(years)Abemaciclib Then Abemaciclib + Clarithromycin
Mean60.0 ± 9.2
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Abemaciclib Then Abemaciclib + Clarithromycin
Female19
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abemaciclib Then Abemaciclib + Clarithromycin
Hispanic or Latino1
Not Hispanic or Latino25
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abemaciclib Then Abemaciclib + Clarithromycin
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American6
White19
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib Then Abemaciclib + Clarithromycin
United States26
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram/square meter (kg/m2))Abemaciclib Then Abemaciclib + Clarithromycin
Mean27.62 ± 6.04
Eastern Cooperative Oncology Group (ECOG) Scale
Eastern Cooperative Oncology Group (ECOG) Scale(participants)Abemaciclib Then Abemaciclib + Clarithromycin
ECOG= 018
ECOG= 18
09

Study locations

2 sites
  • Accelerated Comm. Oncology Research Network (ACORN)
    Memphis, Tennessee 38119, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
10

References and documents

Publications

  • Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13. PubMed 24919854 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Feb 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2014
First posted
Apr 21, 2014
Start
Apr 2014
Primary completionActual
Feb 2015
CompletionActual
Aug 2015
Results first posted
Aug 2, 2018
Last update
Jan 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02117648
Responsible party
Sponsor
First posted
Apr 21, 2014
Start date
Apr 2014
Primary completion
Feb 2015
Completion
Aug 2015
Results posted
Aug 2, 2018
Last update
Jan 7, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion